Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure IV: Classification and Diagnostic Evaluation01:30

Heart Failure IV: Classification and Diagnostic Evaluation

100
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
100
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.1K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.1K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

138
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
138
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

110
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
110
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

111
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
111
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

61
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
61

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SGLT2 Inhibitors in Hypertrophic Cardiomyopathy: Emerging Evidence and Putative Mechanisms.

Biomolecules·2026
Same author

Economic evaluation of adjuvant chemotherapy for non-metastatic sarcoma using the real-world data from the French nationwide DEEPSARC study.

Journal of medical economics·2026
Same author

Overall survival of patients with localized soft tissue sarcoma treated with or without adjuvant chemotherapy (DEEPSARC): a real world nationwide retrospective cohort study in France.

EClinicalMedicine·2026
Same author

Left Ventricular Function and Atrial Remodeling Shape Outcomes After Mitral-Transcatheter Edge-to-Edge Repair.

ESC heart failure·2026
Same author

Multidisciplinary Delphi Consensus on management of children with moderate-severe atopic dermatitis.

Italian journal of pediatrics·2026
Same author

The use of detergents, moisturizers and the experience with therapeutic education among Italian pediatric patients with atopic dermatitis.

Italian journal of pediatrics·2026

Related Experiment Video

Updated: Nov 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K

Phenomapping Heart Failure with Preserved Ejection Fraction Using Machine Learning Cluster Analysis: Prognostic and

Elena Galli1, Corentin Bourg1, Wojciech Kosmala2

  • 1University of Rennes, CHU Rennes, INSERM, LTSI-UMR 1099, Rennes F-35000, France.

Heart Failure Clinics
|May 30, 2021
PubMed
Summary

Heart failure with preserved ejection fraction (HFpEF) has high mortality rates similar to heart failure with reduced ejection fraction (HFrEF). Understanding HFpEF

Keywords:
Heart failure with preserved ejection fractionMachine learningPhenomappingPrecision medicinePrognosisTargeted treatment

More Related Videos

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

334

Related Experiment Videos

Last Updated: Nov 4, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.7K
A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.1K
Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
05:16

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure

Published on: June 10, 2025

334

Area of Science:

  • Cardiology
  • Internal Medicine
  • Clinical Research

Background:

  • Heart failure with preserved ejection fraction (HFpEF) presents significant morbidity and mortality, comparable to heart failure with reduced ejection fraction (HFrEF).
  • Existing treatments for HFrEF are often ineffective for HFpEF due to differing underlying pathologies.
  • The high hospitalization and mortality rates (up to 84% at 5 years) necessitate novel therapeutic approaches for HFpEF.

Purpose of the Study:

  • To review the distinct etiologies and phenotypes of HFpEF.
  • To explore the development of targeted therapeutic strategies based on HFpEF phenotypes.
  • To address the unmet need for effective HFpEF treatments.

Main Methods:

  • Literature review and analysis of epidemiological data on HFpEF and HFrEF.
  • Discussion of the heterogeneous etiologic background of HFpEF.
  • Comparative analysis of HFpEF and HFrEF pathophysiology.

Main Results:

  • HFpEF is characterized by a heterogeneous etiologic background, unlike the primary myocardial damage seen in HFrEF.
  • Identification of distinct HFpEF phenotypes is crucial for understanding disease progression.
  • Current therapeutic strategies require adaptation to address specific HFpEF phenotypes.

Conclusions:

  • Tailoring therapies to specific HFpEF phenotypes is essential for improving patient outcomes.
  • Further research into the diverse causes of HFpEF is required to develop innovative treatments.
  • Addressing the unique characteristics of HFpEF is critical to reduce its substantial morbidity and mortality burden.